1. Chow EJ, Doyle JD, Uyeki TM (2019) Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care 23:214. https://doi.org/10.1186/s13054-019-2491-9
2. Public Health England (2019) PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. Version 10.0. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/833572/PHE_guidance_antivirals_influenza_201920.pdf. Accessed 27 Oct 2019
3. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG (2019) Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200:e45–e67. https://doi.org/10.1164/rccm.201908-1581ST
4. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT (2019) Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis 68:895–902
5. European Centre for Disease Prevention and Control (2019) An agency of the European Union (2019) Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza—review of recent systematic reviews and meta-analyses. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/antivirals/neuraminidase-inhibitors. Accessed 27 Oct 2019